thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
June 08, 2019 – For some time now, Tofacitinib (Xeljanz) receives intense attention in the media, with regulatory authorities, and patients and treating physicians alike because of serious concerns of increased risk of blood clots in the lungs and increased mortality in patients treated for ulcerative colitis at the 10-mg twice-daily dose of Tofacitinib (Xeljanz).
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL),
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
February 17, 2019 – The unfortunate recognition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a very rare form of a T-cell lymphoma, gains more momentum by the day. This is actually very positive a development, because it helps women who are getting breast implants for whatever reasons to better known associated health risks,
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine
No Comments ↓
February 02, 2019 – This is potential alarming news for millions of patients worldwide suffering from high blood pressure: Health Canada has just completed a safety review of hydrochlorothiazide and has found that prolonged use of the drug could increase a person’s risk for non-melanoma skin cancer.
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine
1 Comment ↓
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], Genetic Background, Genetic Predisposition, Genetic Susceptibility, Personalized Medicine, Thasso Post, Theragenomic Medicine
No Comments ↓
thassodotcom
Posted in Adverse Drug Reaction [ADR], Allelic Variant, Children, Clinical Development, Congenital, Gene Therapy, Genetic Predisposition, In The Press, Personalized Medicine, Rare Diseases, Thasso Post, Theragenomic Medicine
No Comments ↓
December 12, 2018 – The application of CRISPR/Cas9 based molecular technology in the field of gene editing (or genome editing) has recently had its exploded limelight exposure for a couple of reasons. The question arises if this exposure is earned or somewhat premature.
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], New Research, New Safety Information, Thasso Post, Theragenomic Medicine
No Comments ↓
October 21, 2018 – In a study published online September 13 in JAMA Oncology, the authors just reminded us of the fact that besides all hype about immune checkpoint inhibitors (ICIs) in the cancer therapy field,
…
thassodotcom
Posted in Adverse Drug Reaction [ADR], New Safety Information, Rare Diseases, Thasso Post, Theragenomic Medicine
No Comments ↓
01 September 2018 – The American Food and Drug Administration (FDA) is warning that cases of a very rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
…
Optional: Social Subscribe/Login
Therapies that promote progressive multifocal leukoencephalopathy (PML)
August 23, 2019 – Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal viral disease characterized by progressive damage or inflammation of the white matter of the brain at multiple locations (i.e., multifocal). It is caused by the JC virus,
…
Read more ›